138 related articles for article (PubMed ID: 34702119)
1. Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies.
Jolles S; Smith BD; Vinh DC; Mallick R; Espinoza G; DeKoven M; Divino V
Leuk Lymphoma; 2022 Jan; 63(1):64-73. PubMed ID: 34702119
[TBL] [Abstract][Full Text] [Related]
2. Infections in secondary immunodeficiency patients treated with Privigen
Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
[TBL] [Abstract][Full Text] [Related]
3. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
4. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.
Shah N; Mustafa SS; Vinh DC
Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
Sim B; Ng JY; Teh BW; Talaulikar D
Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
[TBL] [Abstract][Full Text] [Related]
6. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
[TBL] [Abstract][Full Text] [Related]
7. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
[TBL] [Abstract][Full Text] [Related]
8. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies.
Ochoa-Grullón J; Benavente Cuesta C; Pérez López C; Peña Cortijo A; Rodríguez de la Peña A; Álvarez Carmona A; Mateo Morales M; Llano-Hernández K; Williams LJ; Rodríguez de Frías E; Guevara-Hoyer K; Cordero Torres G; Orte C; Fernández-Arquero M; Fernández-Paredes L; Serrano-García I; Recio MJ; Pérez de Diego R; Martínez R; Sánchez-Ramón S
Clin Immunol; 2020 Jan; 210():108307. PubMed ID: 31760095
[TBL] [Abstract][Full Text] [Related]
10. Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases.
Ballow M; Sánchez-Ramón S; Walter JE
Front Immunol; 2022; 13():928062. PubMed ID: 35924244
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
12. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
13. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China.
Ye C; Liu J; Song X; Zheng S; Liu J
Medicine (Baltimore); 2021 Jan; 100(3):e23935. PubMed ID: 33545966
[TBL] [Abstract][Full Text] [Related]
14. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Hematology; 2019 Dec; 24(1):173-182. PubMed ID: 30458690
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy.
Patel V; Cameron DW; Cowan J
Hematol Oncol; 2021 Oct; 39(4):584-588. PubMed ID: 34288002
[No Abstract] [Full Text] [Related]
16. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.
Khanna N; Widmer AF; Decker M; Steffen I; Halter J; Heim D; Weisser M; Gratwohl A; Fluckiger U; Hirsch HH
Clin Infect Dis; 2008 Feb; 46(3):402-12. PubMed ID: 18181739
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.
Reiser M; Borte M; Huscher D; Baumann U; Pittrow D; Sommer C; Stangel M; Fasshauer M; Gold R; Hensel M
Eur J Haematol; 2017 Aug; 99(2):169-177. PubMed ID: 28467615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
